Literature DB >> 33811554

Cardiac rehabilitation after catheter ablation of atrial fibrillation in patients with left ventricular dysfunction.

Daisetsu Aoyama1, Shinsuke Miyazaki2, Kanae Hasegawa2, Moeko Nagao2, Shota Kakehashi2, Moe Mukai2, Takayuki Sekihara2, Minoru Nodera2, Tomoya Eguchi2, Takayoshi Aiki2, Junya Yamaguchi2, Yuichiro Shiomi2, Naoto Tama2, Hiroyuki Ikeda2, Kentaro Ishida2, Hiroyasu Uzui2, Hiroshi Tada2.   

Abstract

Few studies have examined the efficacy and safety of cardiac rehabilitation in patients with atrial fibrillation (AF) who underwent AF ablation. We explored the feasibility of additional cardiac rehabilitation after AF ablation in patients with a reduced left ventricular ejection fraction (LVEF). Fifty-four patients with heart failure (HF) and a reduced LVEF (HFrEF) (LVEF < 50%; 67.1 ± 11.6 years; 43 men) who underwent initial AF ablation procedures were included. Fourteen (25.9%) patients underwent cardiac rehabilitation (rehabilitation-group) and the remaining 40 (74.1%) did not (non-rehabilitation-group) after the procedure. The rehabilitation-group patients were relatively older, more likely female (p = 0.024), and had more likely a history of an HF hospitalization (p < 0.01) and cardiac device implantation (p = 0.041). The baseline LVEF was significantly lower (p = 0.043) and brain natriuretic peptide (BNP) (p < 0.01) and C-reactive protein (CRP) (p < 0.01) values were significantly higher in the rehabilitation-group. The 6-min walk distance significantly improved after 21.4 ± 11.5 days of cardiac rehabilitation during hospitalization (226.1 ± 155.9 vs. 398.1 ± 77.5 m, p = 0.016) without any adverse events. During an 18.9 ± 6.3 month follow-up period, the freedom from AF recurrence (p = 0.52) and re-hospitalizations due to HF (p = 0.63) were similar between the 2 groups. No death or strokes were observed. During the follow-up period, the LVEF significantly improved similarly in both groups, and the change in the BNP and CRP values significantly decreased in the rehabilitation-group. Despite the rehabilitation-group patients having a more severe HF status, the clinical outcomes and AF freedom were similar between the 2 groups, suggesting the favorable impact of cardiac rehabilitation after AF ablation in HFrEF patients.
© 2021. Springer Japan KK, part of Springer Nature.

Entities:  

Keywords:  Atrial fibrillation; Cardiac rehabilitation; Catheter ablation; Left ventricular dysfunction

Mesh:

Substances:

Year:  2021        PMID: 33811554     DOI: 10.1007/s00380-021-01829-8

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  2 in total

1.  Clinical outcomes of ablation versus non-ablation therapy for atrial fibrillation in Japan: analysis of pooled data from the AF Frontier Ablation Registry and SAKURA AF Registry.

Authors:  Kazuki Iso; Koichi Nagashima; Masaru Arai; Ryuta Watanabe; Katsuaki Yokoyama; Naoya Matsumoto; Takayuki Otsuka; Shinya Suzuki; Akio Hirata; Masato Murakami; Mitsuru Takami; Masaomi Kimura; Hidehira Fukaya; Shiro Nakahara; Takeshi Kato; Hiroshi Hayashi; Yu-Ki Iwasaki; Wataru Shimizu; Ikutaro Nakajima; Tomoo Harada; Junjiroh Koyama; Ken Okumura; Michifumi Tokuda; Teiichi Yamane; Kojiro Tanimoto; Yukihiko Momiyama; Noriko Nonoguchi; Kyoko Soejima; Koichiro Ejima; Nobuhisa Hagiwara; Masahide Harada; Kazumasa Sonoda; Masaru Inoue; Koji Kumagai; Hidemori Hayashi; Yoshinao Yazaki; Kazuhiro Satomi; Yuji Watari; Yasuo Okumura
Journal:  Heart Vessels       Date:  2020-11-24       Impact factor: 2.037

2.  Age modifies the risk of atrial fibrillation among athletes: A systematic literature review and meta-analysis.

Authors:  Hakeem Ayinde; Marin L Schweizer; Victoria Crabb; Adedayo Ayinde; Ashraf Abugroun; James Hopson
Journal:  Int J Cardiol Heart Vasc       Date:  2018-02-18
  2 in total
  1 in total

1.  Efficacy and Safety of a Combined Aerobic, Strength and Flexibility Exercise Training Program in Patients with Implantable Cardiac Devices.

Authors:  Maria Rosaria Squeo; Barbara Di Giacinto; Marco Alfonso Perrone; Massimo Santini; Maria Luisa Sette; Emanuele Fabrizi; Antonia Vaquer; Attilio Parisi; Antonio Spataro; Alessandro Biffi
Journal:  J Cardiovasc Dev Dis       Date:  2022-06-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.